47.33
-2.60 (-5.21%)
| Previous Close | 49.93 |
| Open | 49.84 |
| Volume | 132,935 |
| Avg. Volume (3M) | 213,068 |
| Market Cap | 1,482,328,320 |
| Price / Book | 2.90 |
| 52 Weeks Range | |
| Earnings Date | 7 Nov 2024 - 11 Nov 2024 |
| Diluted EPS (TTM) | -3.62 |
| Total Debt/Equity (MRQ) | 0.38% |
| Current Ratio (MRQ) | 25.02 |
| Return on Assets (TTM) | -15.51% |
| Return on Equity (TTM) | -21.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Disc Medicine, Inc. | Bullish | Bearish |
Stockmoo Score
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.63 |
|
Disc Medicine Inc is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. The company is building a portfolio of inventive therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease. The Company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.51% |
| % Held by Institutions | 98.26% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 85.00 (Cantor Fitzgerald, 79.59%) | Buy |
| Median | 70.00 (47.90%) | |
| Low | 57.00 (Wedbush, 20.43%) | Buy |
| Average | 69.80 (47.48%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 47.03 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 16 Oct 2024 | 62.00 (31.00%) | Buy | 47.99 |
| Cantor Fitzgerald | 15 Oct 2024 | 85.00 (79.59%) | Buy | 47.64 |
| 20 Sep 2024 | 85.00 (79.59%) | Buy | 48.11 | |
| HC Wainwright & Co. | 16 Sep 2024 | 70.00 (47.90%) | Buy | 47.68 |
| Wells Fargo | 22 Aug 2024 | 75.00 (58.46%) | Buy | 48.75 |
| Wedbush | 09 Aug 2024 | 57.00 (20.43%) | Buy | 43.09 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Oct 2024 | Announcement | Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week |
| 19 Sep 2024 | Announcement | Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer |
| 30 Aug 2024 | Announcement | Disc Medicine to Participate in Upcoming Investor Conferences |
| 08 Aug 2024 | Announcement | Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |